AUPH Q1 2023 Earnings — Aurinia Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

AUPHAurinia Pharmaceuticals Inc.

$2B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$34M+59.1% YoY

Gross Profit

$34M98.8% margin

Operating Income

-$30M-86.0% margin

Net Income

-$26M-76.2% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

+21.0%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$32M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$452M

Total Liabilities

$61M

Stockholders' Equity

$390M

Cash & Equivalents

$89M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$34M	$22M	+59.1%
Gross Profit	$34M	$21M	+59.1%
Operating Income	-$30M	-$38M	+21.9%
Net Income	-$26M	-$38M	+30.4%

Revenue Segments

Product

$34M100%

License, Royalty and Collaboration Revenue

$72,0000%